Program
Target
PGRN
Candidate
Phase 3
Indication
FTD-GRN
Alector’s Commercial Ownership
Rights
Target
PGRN
Candidate
Phase 2
Indication
AD
Alector’s Commercial Ownership
Rights
Program
Target
Aβ
Candidate
Preclinical
Indication
AD
Rights
Target
GCase
Candidate
Preclinical
Indication
PD, LBD
Rights
Target
Reelin
Candidate
Preclinical
Indication
AD
Rights
Target
Tau
Candidate
Research
Indication
AD, FTD
Rights
Target
Tau
Candidate
Research
Indication
AD, FTD
Rights
Close
PGRN
Frontotemporal dementia (FTD) in granulin mutation
Phase 3
AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.
Close
PGRN
Neurodegenerative diseases
Phase 2
AL101 is designed to increase progranulin levels for the treatment of more prevalent neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.
AL101 is currently being studied in a Phase 1 clinical trial of healthy volunteers designed to assess safety, tolerability and pharmacokinetics and pharmacodynamics. AL101 is being developed in collaboration with GSK.
Close
Aβ
AD
Preclinical
ADP037-ABC is a proprietary anti-amyloid beta (Aβ) antibody paired with the company’s ABC for the treatment of AD. It is designed to remove brain amyloid plaques, with the potential to reduce the risk of amyloid-related imaging abnormalities (ARIA) and enable subcutaneous delivery. It targets a validated epitope specific to brain amyloid plaques, combined with an optimized antibody constant region to enhance phagocytosis of Aβ plaques. By leveraging ABC technology, ADP037-ABC aims to clear Aβ efficiently, thereby reducing plaque accumulation and slowing disease progression while minimizing ARIA.
Close
GCase
PD, LBD
Preclinical
ADP050-ABC is a GCase replacement therapy paired with the company’s proprietary ABC for GBA gene mutation carriers with Parkinson’s disease and Lewy body dementia. In these patients, mutations in the GBA gene lead to deficient GCase activity. ADP050-ABC uses Alector-engineered GCase, which has been designed to have a longer half-life and to break down glucocerebroside, a lipid that accumulates in neurons and contributes to neurodegeneration. This mechanism aims to reduce cellular dysfunction and slow disease progression.
Close
Reelin
AD
Preclinical
ADP056 is a reelin modulator designed to block tau pathology and promote synaptic function in AD. Reelin, a large, secreted protein, regulates neuronal function and tau accumulation. Gain-of-function reelin variants protect against familial AD through a mechanism that appears to uncouple amyloid and tau pathology. ADP056 is designed to mimic and exceed these protective effects of the reelin mutation.
Close
Tau
AD
Research
ADP063-ABC targets tau pathology in Alzheimer’s disease. It combines a proprietary anti-tau antibody with Alector Brain Carrier and an optimized antibody constant region. It is designed to block the spread of tau aggregates and has the potential for subcutaneous delivery, with the aim of potentially slowing cognitive decline.
Close
Tau
AD
Research
ADP064-ABC targets tau pathology in Alzheimer’s disease. It combines an anti tau siRNA, which aims to prevent the synthesis of the tau mRNA and protein, with Alector Brain Carrier, to potentially slow cognitive decline.
ABC = Alector Brain Carrier
AD = Alzheimer’s Disease
PD = Parkinson’s Disease
LBD = Lewy Body Dementia